Sign In
Buy AXGN
$42.21
+0.86 (+2.08%)
At Close: Jul 31, 2026
AxoGen (AXGN) Surges 8.2%: Is This an Indication of Further Gains?
08:29am, Monday, 14'th Oct 2024
AxoGen (AXGN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in t
First September Gains in 5 Years? Buy 3 Breakout Stocks Now
04:06pm, Monday, 23'rd Sep 2024
Bioventus, Great Lakes Dredge & Dock, and AxoGen have been selected as the breakout stocks for today.
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
07:00am, Friday, 06'th Sep 2024
ALACHUA, Fla. and TAMPA, Fla., Sept. 06, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries,
AxoGen, Inc. (AXGN) Hit a 52 Week High, Can the Run Continue?
10:16am, Wednesday, 04'th Sep 2024
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
What Makes AxoGen (AXGN) a Strong Momentum Stock: Buy Now?
01:01pm, Friday, 30'th Aug 2024
Does AxoGen (AXGN) have what it takes to be a top stock pick for momentum investors? Let's find out.
Wall Street Analysts See a 25.51% Upside in AxoGen (AXGN): Can the Stock Really Move This High?
10:55am, Friday, 23'rd Aug 2024
The mean of analysts' price targets for AxoGen (AXGN) points to a 25.5% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts
AxoGen, Inc. (AXGN) Hits Fresh High: Is There Still Room to Run?
10:15am, Monday, 19'th Aug 2024
AxoGen (AXGN) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
Apple, Inc. (AXGN) Q2 2024 Earnings Call Transcript
02:10pm, Thursday, 08'th Aug 2024
AxoGen, Inc. (NASDAQ:AXGN ) Q2 2024 Earnings Conference Call August 8, 2024 8:00 AM ET Company Participants Harold Tamayo - Vice President-Finance and Investor Relations Karen Zaderej - Chairman, Chie
AxoGen (AXGN) Q2 Earnings and Revenues Beat Estimates
09:21am, Thursday, 08'th Aug 2024
AxoGen (AXGN) came out with quarterly earnings of $0.05 per share, beating the Zacks Consensus Estimate of a loss of $0.05 per share. This compares to loss of $0.03 per share a year ago.
Axogen, Inc. Announces New Leadership Appointments
07:05am, Thursday, 08'th Aug 2024
ALACHUA, Fla. and TAMPA, Fla., Aug. 08, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, t
AxoGen (AXGN) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
11:06am, Thursday, 01'st Aug 2024
AxoGen (AXGN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
07:00am, Tuesday, 23'rd Jul 2024
ALACHUA and TAMPA, Fla., July 23, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, today a
AxoGen (AXGN) Soars 8.2%: Is Further Upside Left in the Stock?
09:41am, Friday, 12'th Jul 2024
AxoGen (AXGN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
07:00am, Monday, 01'st Jul 2024
ALACHUA, Fla. and TAMPA, Fla., July 01, 2024 (GLOBE NEWSWIRE) -- Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for peripheral nerve injuries, a
AxoGen's (AXGN) New Launch to Aid Peripheral Nerve Protection
01:55pm, Tuesday, 25'th Jun 2024
AxoGen (AXGN) announces the full launch of its Avive+ Soft Tissue Matrix to provide comprehensive solutions for nerve protection.
